Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04214392
Other study ID # 19309
Secondary ID NCI-2019-0839319
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 26, 2020
Est. completion date August 31, 2025

Study information

Verified date March 2024
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.


Description:

PRIMARY OBJECTIVES: I. Assess the feasibility and safety of dual delivery of chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs (chlorotoxin [CLTX]-CAR T cells) for participants with MMP2+ recurrent or progressive glioblastoma. II. Determine the maximum tolerated dose schedule (MTD) and a recommended phase 2 dosing plan (RP2D) for dual delivery of CLTX-CAR T cells for participants with MMP2+ recurrent or progressive glioblastoma. SECONDARY OBJECTIVES: I. Describe persistence, expansion, and phenotype of endogenous and CLTX-CAR CAR T cells in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF). II. Describe cytokine levels in PB, TCF, and CSF over the study period. III. In research participants who receive the full schedule of 3 cycles of CLTX-CAR T cells: IIIa. Estimate the six month progression free survival (PFS) rate. IIIb. Estimate the nine month overall survival (OS) rate. IIIc. Estimate disease response rates. IIId. Estimate median overall survival (OS). IV. In study participants who undergo an additional biopsy/resection or autopsy: IVa. Evaluate CAR T cell persistence in the tumor tissue and the location of the CAR T cells with respect to the injection site. IVb. Evaluate CLTX-targeted antigen expression levels on tumor tissue pre and post CAR T cell therapy. V. Use mathematical modeling of tumor growth to evaluate benefit of treatment. OUTLINE: This is a dose-escalation study. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one or two CAR T cell infusions (one at each catheter site) and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, 3, 6, 9, and 12 months, and then yearly for up to 15 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date August 31, 2025
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Documented informed consent of the participant and/or legally authorized representative. Assent, when appropriate, will be obtained per institutional guidelines. Note: For research participants who do not speak English, a short form consent may be used with a COH certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated main consent is processed. However, the research participant is allowed to proceed with surgery/rickham placement and CAR T cell infusion only after the translated main consent form is signed. - Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with study principal investigator (PI) approval - Karnofsky performance status (KPS) >= 60% - Eastern Cooperative Oncology Group (ECOG) =< 2 - Life expectancy >= 4 weeks - Participant has a prior histologically-confirmed diagnosis of a grade IV glioblastoma, or has a prior histologically-confirmed diagnosis of a grade II or III malignant brain tumors and now has radiographic progression consistent with a grade IV glioblastoma - Relapsed disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy, and >= 12 weeks after completion of front-line radiation therapy - City of Hope (COH) Clinical Pathology confirms matrix metalloproteinase (MMP)2+ tumor expression by immunohistochemistry (>= 20% moderate/high MMP2 [2+/3+]) - No known contraindications to leukapheresis, steroids, or tocilizumab - White blood cell (WBC) > 2000 /dl (or absolute neutrophil count [ANC] >= 1,000/mm^3) (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Platelets >= 75,000/mm^3 (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Hemoglobin >= 8 g/dl (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Total bilirubin =< 1.5 upper limit of normal (ULN) (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Aspartate aminotransferase (AST) =< 2.5 x ULN (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Alanine aminotransferase (ALT) =< 2.5 x ULN (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Serum creatinine =< 1.6 mg/dL (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Oxygen (O2) saturation >= 95% on room air (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed within 14 days prior to leukapheresis unless otherwise stated) - If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required - Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of CAR T cells - Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only) Exclusion Criteria: - Prior and concomitant therapies - Owing to higher frequency of wound-related complications, participants who are within 3 months of having received prior bevacizumab therapy at the time of enrollment are excluded. - Participant has not yet recovered from toxicities of prior therapy - Other illnesses or conditions - Uncontrolled seizure activity and/or clinically evident progressive encephalopathy - History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent - Active diarrhea - Clinically significant uncontrolled illness - Active infection requiring antibiotics - Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection - Other active malignancy - Females only: Pregnant or breastfeeding - Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures - Noncompliance - Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Study Design


Intervention

Biological:
Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
Given via ICT delivery
Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
Given via ICT/ICV dual delivery

Locations

Country Name City State
United States City of Hope Medical Center Duarte California

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity (DLT) Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Rate and associated 90% Clopper and Pearson binomial confidence limits (90% confidence interval) will be estimated for participants experiencing DLTs at the recommended phase 2 dose schedule. Tables will be created to summarize all toxicities and side effects by dose, time post treatment, organ, severity, and arm. 2. Cytokine Release Syndrome (CRS) 3. All other toxicities. 28 days
Secondary Chimeric antigen receptor (CAR) T cell Will assess its levels and phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) (absolute number per ul by flowcytometry). Statistical and graphical methods will be used. 15 years
Secondary Endogenous T cell Will assess its level and phenotype detected in TCF, PB, and CSF (absolute number per ul by flowcytometry). Statistical and graphical methods will be used. 15 years
Secondary Cytokine levels in TCF, PB and CSF 15 years
Secondary Progression free survival time At 6 months
Secondary Disease response Will be assessed by modified Response Assessment in Neuro-Oncology Criteria (RANO) criteria with the need for bevacizumab as an additional indicator of progression. At 6 months
Secondary Overall survival (OS) Kaplan Meier methods will be used to estimate median OS and graph the results. At 9 months
Secondary CAR T cells detected in tumor tissue Will be assessed by immunohistochemistry. 15 years
Secondary Chlorotoxin-targeted antigen expression levels in tumor tissue Will assess the pathology H score. 15 years
Secondary Biomathematical modeling of tumor growth Will assess perfusion and growth parameters based on serial brain magnetic resonance imaging (MRI)s. 15 years
See also
  Status Clinical Trial Phase
Recruiting NCT05577091 - Tris-CAR-T Cell Therapy for Recurrent Glioblastoma Phase 1
Recruiting NCT05284643 - Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma N/A
Recruiting NCT05039281 - Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT04988750 - Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients N/A
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT00503204 - Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour Phase 1
Completed NCT03216499 - HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma Phase 2
Not yet recruiting NCT04717999 - Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma N/A
Not yet recruiting NCT05540275 - Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma Phase 2
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT04044937 - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms Phase 2
Recruiting NCT04888611 - Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma Phase 2
Completed NCT00390299 - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1
Recruiting NCT05463848 - Surgical Pembro +/- Olaparib w TMZ for rGBM Phase 2
Active, not recruiting NCT04479241 - LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma Phase 2
Active, not recruiting NCT00777153 - Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Phase 3
Withdrawn NCT05017610 - Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma Early Phase 1
Recruiting NCT04323046 - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Phase 1
Active, not recruiting NCT05324501 - A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma Phase 1
Withdrawn NCT05666349 - Reirradiation and Niraparib in Patients With Recurrent Glioblastoma Phase 1